Recoupedrol is high in glycoside content and backed with 4 human clinical, Toxicological and preclinical studies. The manufacturing process for Recoupedrol uses cane ethanol and water only. Additionally, it is soluble in water. Recoupedrol is also Human safety assessed for one year
Safety of Recoupedrol has been evaluated in 4 different toxicological studies as per
A. Acute toxicity in rats-LD50> 2000 mg/kg
B. 90 day repeated dose oral toxicity in rats-No Observed Adverse Effect Level
(NOAEL) at 1000 mg/kg in male rats & 500 mg/kg in female rats.
C. In-vitro bacterial reverse mutation assay (AMES Test)-
a. Maximum concentration = 5000 mcg/plate
b. Recoupedrol is not mutagenic
D. Pre-natal developmental toxicity study- NOAEL at 1000 mg/kg
Anti-aging effect of Recoupedrol on facial skin evaluated in women by Monocentric, double-blinded, placebo-controlled, randomised parallel study
Monocentric, double-blinded, placebo-controlled, randomised parallel study
Total 50 women of average age 45 years participated
Placebo (25 subjects participated and all of them completed)
Recoupedrol (25 subjects participated and 23 completed)
Recoupedrol showed significant improvement in skin elasticity, skin roughness and collagen distribution on day 30 from baseline whereas placebo did not show these improvements from baseline. Also, skin barrier properties are maintained on day 30 and day 60.
In-vitro Franz diffusion cells
Human cadaver skin
Recoupedrol diffused up till epidermis and dermis.
Recoupedrol didn’t enter the receptor fluid
In-vitro Franz diffusion cells
Recoupedrol enters the receptor fluid because there was no dermis and epidermis.
Method-Primary cell culture of NHEK (normal human epidermis keratinocytes) isolated from human adult foreskin. Keratinocytes were cultured in Keratinocyte-SFM (Gibco BRL/Invitrogen, Carlsbad, CA, USA) supplemented with rEGF (0.1-0.2 ng/ml), bovine pituitary extract (20-30 μg/ml), and 1% penicillin/streptomycin
In confluence differentiation model, early differentiation markers involucrin (INV) and transglutaminase (TGase) and late differentiation markers Keratin K10 and loricrin are all increased. Silencing EGFR can decrease INV but increase K10 and loricrin expression, indicating endogenous EGF/EGFR is involved to regulate early markers but interfere with late markers expression
In culture medium containing low concentration of EGF, EGFR inhibitor gefitinib inhibits early markers (INV, TGase), but increases late marker (loricrin). p63 downregulation required for differentiation was also induced by gefitinib. In contrast to the effects of gefitinib, Recoupedrol increases protein expression of INV and TGase but decreases protein expression of loricrin in NHEK cultured in complete medium. Similar to gefitinib, IND830 decreases p63 expression
Suitable ingredient for health products in the form of capsules, tablets, beverages, cosmetics, energy bars etc.
The information given on the website has not been evaluated by any regulatory authority. These ingredients are not intended to diagnose, treat, cure or prevent any disease. The manufacturer making use of these ingredients and the information given on the website is responsible to ensure the compliance of the claims and their use according to the regulatory requirements of their respective country.